163 related articles for article (PubMed ID: 14511299)
1. Surveillance of infectious complications associated with central venous access devices in children with haemophilia.
Tarantino MD; Lail A; Donfield SM; Lynn H; Peddle L; Hunsberger S; Shapiro AD
Haemophilia; 2003 Sep; 9(5):588-92. PubMed ID: 14511299
[TBL] [Abstract][Full Text] [Related]
2. Central venous access device-related infections in patients with haemophilia.
Yeoh ZH; Furmedge J; Ekert J; Crameri J; Curtis N; Barnes C
J Paediatr Child Health; 2013 Mar; 49(3):242-5. PubMed ID: 23438133
[TBL] [Abstract][Full Text] [Related]
3. Central venous access devices for paediatric patients with haemophilia: a single-institution experience.
Titapiwatanakun R; Moir C; Pruthi RK; Stavlo PL; Schmidt KA; Rodriguez V
Haemophilia; 2009 Jan; 15(1):168-74. PubMed ID: 19149849
[TBL] [Abstract][Full Text] [Related]
4. Central venous access device (CVAD) complications in Haemophilia with inhibitors undergoing immune tolerance induction: Lessons from the international immune tolerance study.
Rodriguez V; Mancuso ME; Warad D; Hay CR; DiMichele DM; Valentino L; Kenet G; Kulkarni R
Haemophilia; 2015 Sep; 21(5):e369-74. PubMed ID: 26178581
[TBL] [Abstract][Full Text] [Related]
5. Monthly recombinant tissue plasminogen activator administration to implantable central venous access devices decreases infections in children with haemophilia.
Jeng MR; O'Brien M; Wong W; Zoland J; Lea J; Tang N; Glader B
Haemophilia; 2009 Nov; 15(6):1272-80. PubMed ID: 19601989
[TBL] [Abstract][Full Text] [Related]
6. Complications of central venous catheters in patients with haemophilia and inhibitors.
Morado M; Jimenez-Yuste V; Villar A; Quintana M; Del Castillo F; Garzon G; Acitores I; Ibañez F; Sanjurjo MJ; Gago J; Hernandez-Navarro F
Haemophilia; 2001 Nov; 7(6):551-6. PubMed ID: 11851752
[TBL] [Abstract][Full Text] [Related]
7. Overview of the use of implantable venous access devices in the management of children with inherited bleeding disorders.
Komvilaisak P; Connolly B; Naqvi A; Blanchette V
Haemophilia; 2006 Dec; 12 Suppl 6():87-93. PubMed ID: 17123400
[TBL] [Abstract][Full Text] [Related]
8. Complications associated with central venous access device in children with haemophilia: a nationwide multicentre study in Finland.
Vepsäläinen K; Lassila R; Arola M; Lähteenmäki P; Möttönen M; Mäkipernaa A; Riikonen P
Haemophilia; 2015 Nov; 21(6):747-53. PubMed ID: 25832453
[TBL] [Abstract][Full Text] [Related]
9. Central venous access devices in children with congenital coagulation disorders: complications and long-term outcome.
McMahon C; Smith J; Khair K; Liesner R; Hann IM; Smith OP
Br J Haematol; 2000 Aug; 110(2):461-8. PubMed ID: 10971409
[TBL] [Abstract][Full Text] [Related]
10. The use of central venous catheters (portacaths) in children with haemophilia.
Bollard CM; Teague LR; Berry EW; Ockelford PA
Haemophilia; 2000 Mar; 6(2):66-70. PubMed ID: 10781190
[TBL] [Abstract][Full Text] [Related]
11. Complications of central venous access devices in children with and without cancer.
Tobiansky R; Lui K; Dalton DM; Shaw P; Martin H; Isaacs D
J Paediatr Child Health; 1997 Dec; 33(6):509-14. PubMed ID: 9484682
[TBL] [Abstract][Full Text] [Related]
12. Implantable venous access devices in children with severe hemophilia: a tertiary pediatric institutional experience.
Bedoya MA; Raffini L; Durand R; Acord MR; Srinivasan A; Krishnamurthy G; Vatsky S; Escobar F; Cahill AM
Pediatr Radiol; 2020 Jul; 50(8):1148-1155. PubMed ID: 32390060
[TBL] [Abstract][Full Text] [Related]
13. Updated analysis: central venous access device infection rates in an expanded cohort of paediatric patients with severe haemophilia receiving prophylactic recombinant tissue plasminogen activator.
McCarthy CE; O'Brien M; Andrews J; Zoland JM; Macasiray E; Wong W; Lo C; Glader B; Tamaresis J; Jeng M
Haemophilia; 2016 Jan; 22(1):81-6. PubMed ID: 26248602
[TBL] [Abstract][Full Text] [Related]
14. Central venous access devices in haemophilia.
Valentino LA; Ewenstein B; Navickis RJ; Wilkes MM
Haemophilia; 2004 Mar; 10(2):134-46. PubMed ID: 14962202
[TBL] [Abstract][Full Text] [Related]
15. Tissue plasminogen activator to prevent central venous access device infections: a systematic review of central venous access catheter thrombosis, infection and thromboprophylaxis.
Ragni MV; Journeycake JM; Brambilla DJ
Haemophilia; 2008 Jan; 14(1):30-8. PubMed ID: 18005145
[TBL] [Abstract][Full Text] [Related]
16. Consensus recommendations for use of central venous access devices in haemophilia.
Ewenstein BM; Valentino LA; Journeycake JM; Tarantino MD; Shapiro AD; Blanchette VS; Hoots WK; Buchanan GR; Manco-Johnson MJ; Rivard GE; Miller KL; Geraghty S; Maahs JA; Stuart R; Dunham T; Navickis RJ
Haemophilia; 2004 Sep; 10(5):629-48. PubMed ID: 15357790
[TBL] [Abstract][Full Text] [Related]
17. Central venous access device infections in children with hemophilia: a comparison of prophylaxis and episodic therapy.
Hacker MR; Page JH; Shapiro AD; Rich-Edwards JW; Manco-Johnson MJ
J Pediatr Hematol Oncol; 2007 Jul; 29(7):458-64. PubMed ID: 17609623
[TBL] [Abstract][Full Text] [Related]
18. Long-term central venous access in patients with sickle cell disease. Incidence of thrombotic and infectious complications.
Abdul-Rauf A; Gauderer M; Chiarucci K; Berman B
J Pediatr Hematol Oncol; 1995 Nov; 17(4):342-5. PubMed ID: 7583391
[TBL] [Abstract][Full Text] [Related]
19. Experience with central venous access devices (CVADs) in the Canadian hemophilia primary prophylaxis study (CHPS).
Langley AR; Stain AM; Chan A; McLimont M; Chait S; Wu J; Poon MC; Card R; Israels SJ; Laferriere N; Klaassen RJ; Rivard GE; Cloutier S; Hawes S; Feldman B; Blanchette V
Haemophilia; 2015 Jul; 21(4):469-76. PubMed ID: 26104147
[TBL] [Abstract][Full Text] [Related]
20. Complications of central venous access devices in paediatric haemophilia patients.
Domm JA; Hudson MG; Janco RL
Haemophilia; 2003 Jan; 9(1):50-6. PubMed ID: 12558778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
